Aprea focuses on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53.
Aprea Therapeutics has raised €5.0M across 1 funding round from 1 investor, most recently a Series C round in Jan 2019. Based in Stockholm, Sweden; founded 2003; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2019-01-01 | Series C |
| €5.0M |
| Janus Henderson Investors |
| View deal → |
